October 22, 2016 2:12 PM ET


Company Overview of Targazyme, Inc.

Company Overview

Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...

3200 County Road 104

Floresville, TX 78114

United States

Founded in 2005



Key Executives for Targazyme, Inc.

Co-Founder, Chairman and Chief Executive Officer
Head of Operations and Vice President of CMC
Age: 50
Senior Vice President of Regulatory Affairs & Quality Assurance
Age: 73
Chief Business Officer
Vice President of Clinical Development & Regulatory Affairs
Compensation as of Fiscal Year 2016.

Targazyme, Inc. Key Developments

Targazyme Enrolls First Patient in Phase 1/2 Study of TZ101 Fucosylated Regulatory T Cells

Targazyme, Inc. announced that it has enrolled the first patient in a Phase 1/2 TZ 101-treated regulatory T cell clinical study. This Phase 1/2 clinical study will evaluate the efficacy and safety of TZ101-treated regulatory T cells in the prevention and treatment of acute and chronic Graft-Versus-Host-Disease ("GVHD") in stem cell transplants. This clinical milestone will hopefully translate into the clinic the recent preclinical findings published in the journal Blood demonstrating the effectiveness of ex vivo treatment of regulatory T-cells with TZ101 in the prevention of GVHD.

Targazyme, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 11:45 AM

Targazyme, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 11:45 AM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States.

Targazyme Collaborates with the University of Minnesota Medical Center

Targazyme has collaborated with the University of Minnesota Medical Center. It was reported that the collaboration is aimed at advancing the development of the company's clinical product candidate, TZ101 for use with regulatory T cells. It is based on positive proof of concept data published in the journal 'Blood' demonstrating that ex vivo treatment of Tregs with TZ101 prior to administration is an effective strategy for the prevention of Graft-Versus-Host-Disease. The new partnership will concentrate on improving understanding of the mechanisms involved with TZ101-treated Treg immunotherapy in the transplant and autoimmune disease settings.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Targazyme, Inc., please visit targazyme.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.